Revolution Medicines: Highly Differentiated Offering Gaining Traction
Seeking Alpha,
Follow Summary Revolution Medicines, Inc. has a highly differentiated portfolio of RAS(ON) and RAS companion inhibitors that's…
SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer
Overview of attention for article published in Oncogene, October 2020
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (87th percentile)
-
High Attention Score compared to outputs of the same age and source (97th percentile)
Readers on
- mendeley
- 95 Mendeley